ADIL Logo

Adial Pharmaceuticals, Inc. (ADIL) 

NASDAQ
Market Cap
$6.85M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
515 of 963
Rank in Industry
277 of 552

Largest Insider Buys in Sector

ADIL Stock Price History Chart

ADIL Stock Performance

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Insider Activity of Adial Pharmaceuticals, Inc.

Over the last 12 months, insiders at Adial Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Adial Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Adial Pharmaceuticals, Inc. have bought $53,027 and sold $399,250 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 700 shares for transaction amount of $1,918 was made by Schuyler Kevin (director) on 2023‑09‑29.

List of Insider Buy and Sell Transactions, Adial Pharmaceuticals, Inc.

2023-09-29Purchasedirector
700
0.0566%
$2.74$1,918-45.86%
2021-12-30Purchasedirector
25,000
0.1356%
$2.69$67,300-53.00%
2021-11-30PurchaseChief Executive Officer
10,600
0.0565%
$2.75$29,179-51.80%
2021-11-29PurchaseChief Executive Officer
10,000
0.0544%
$2.59$25,892-47.27%
2021-11-26Purchasedirector
10,000
0.0538%
$2.85$28,500-52.28%
2021-04-06SaleChief Medical Officer
150,000
0.8494%
$2.50$375,000+4.38%
2020-08-20SaleChief Medical Officer
350,000
2.0553%
$1.21$423,500+47.02%
2020-03-27Purchasedirector
19,644
0.1848%
$1.36$26,769+23.91%
2020-03-26PurchaseChief Executive Officer
12,652
0.1363%
$1.47$18,598+31.54%
2020-03-25PurchaseChief Executive Officer
12,348
0.1072%
$1.13$13,953+37.90%
2019-12-12SaleChief Medical Officer
150,000
0.8506%
$1.00$150,000-7.45%
2019-03-29PurchaseChief Medical Officer
33,100
0.4057%
$3.47$114,801-50.44%
2019-03-28PurchaseChief Medical Officer
40,000
0.4706%
$3.15$125,808-47.53%
2018-07-31PurchaseChief Executive Officer
80,000
1.8029%
$5.00$400,000-28.75%
2018-07-31Purchasedirector
180,000
2.0282%
$2.50$450,000-28.75%
2018-07-31Purchasedirector
20,000
0.4507%
$5.00$100,000-28.75%
2018-07-31Purchasedirector
14,000
0.3155%
$5.00$70,000-28.75%
2018-07-31Purchasedirector
14,000
0.3549%
$5.63$78,750-28.75%
2018-07-31Purchase
1,400
0.0316%
$5.00$7,000-28.75%

Insider Historical Profitability

<0.0001%
Stilley William B. IIIChief Executive Officer
937646
14.6375%
$1.0750<0.0001%
Johnson Bankole A.Chief Medical Officer
548336
8.56%
$1.0733<0.0001%
Gilliland Robertson H.director
109424
1.7082%
$1.0710<0.0001%
Newman James W. Jr.director
50221
0.784%
$1.0740<0.0001%
Goodman Tonydirector
8755
0.1367%
$1.0710<0.0001%
Schuyler Kevindirector
700
0.0109%
$1.0720<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.